Article Detail - JE Part B
MolDX: Melanoma Risk Stratification Molecular Testing (L37750) Final LCD - Effective August 08, 2022
This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV). Responses to comments received may be found as a link at the bottom of the final LCD.
Medicare Coverage Database (MCD) Number/Contractor Determination Number: L37750
LCD Title: MolDX: Melanoma Risk Stratification Molecular Testing
Effective Date: August 08, 2022
Summary of LCD: This policy describes and clarifies coverage for molecular diagnostic tests used to assist in risk stratification of melanoma patients.
Visit the Proposed LCDs webpage to access this LCD.